Patents Examined by Bruce Kifle
-
Patent number: 10561739Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.Type: GrantFiled: April 11, 2019Date of Patent: February 18, 2020Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITEDInventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
-
Patent number: 10450263Abstract: The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, chikungunya, Venezuelan equine encephalitis, dengue, influenza, and zika, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: February 8, 2018Date of Patent: October 22, 2019Assignee: Southern Research InstituteInventors: Ashish Kumar Pathak, Syed Kaleem Ahmed, Corinne E. Augelli-Szafran, Joseph A. Maddry
-
Patent number: 10172860Abstract: Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: GrantFiled: July 25, 2017Date of Patent: January 8, 2019Assignee: GILEAD SCIENCES, INC.Inventors: Manoj C. Desai, Randall L. Halcomb, Paul Hrvatin, Hon Chung Hui, Ryan McFadden, Paul A. Roethle, Hong Yang
-
Patent number: 9133170Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: December 13, 2012Date of Patent: September 15, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: John A. Brinkman, Ramakanth Sarabu, Sung-Sau So
-
Patent number: 9045501Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.Type: GrantFiled: March 10, 2014Date of Patent: June 2, 2015Assignee: Albany Molecular Research, Inc.Inventors: Peter R. Guzzo, David D. Manning, William Earley
-
Patent number: 8859536Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.Type: GrantFiled: May 18, 2012Date of Patent: October 14, 2014Assignee: GlaxoSmithKline Intellectual Property (No.2) LimitedInventors: Donghui Qin, Mui Cheung, Hemant Joshi, Raghuram Tangirala, Sridhar Reddy Bethi
-
Patent number: 8741904Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: GrantFiled: July 25, 2013Date of Patent: June 3, 2014Assignee: Alfa Wassermann S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
-
Patent number: 7160875Abstract: The invention relates to malonamide derivatives of formula wherein each of the variables are as defined herein and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures thereof. These compounds are ?-secretase inhibitors and may be used for the treatment of Alzheimer's disease.Type: GrantFiled: September 2, 2004Date of Patent: January 9, 2007Assignee: Hoffmann-La Rache Inc.Inventors: Alexander Flohr, Guido Galley, Roland Jakob-Roetne, Eric Argirios Kitas, Jens-Uwe Peters, Wolfgang Wostl
-
Patent number: 6861438Abstract: The invention provides a compound of formula I: wherein G, R2, and R3 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.Type: GrantFiled: January 14, 2003Date of Patent: March 1, 2005Assignee: PfizerInventors: Scott D. Larsen, Paul May, Karen Romines, Mark E. Schnute, Steven P. Tanis
-
Patent number: 6664253Abstract: The invention relates to new compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, X and Ar1 have the meanings given in the specification, as well as the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.Type: GrantFiled: October 16, 2001Date of Patent: December 16, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Horst Dollinger, Franz Esser, Birgit Jung, Gerd Schnorrenberg, Kurt Schromm, Georg Speck
-
Patent number: 6602866Abstract: This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds.Type: GrantFiled: April 8, 2002Date of Patent: August 5, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Gary A. Flynn, Barbara A. Anderson, Manfred Gerken, Bernd Jablonka, Heinz-Werner Kleemann, Wolfgang Linz, Werner Seiz, Bernhard Seuring
-
Patent number: 6573259Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.Type: GrantFiled: October 23, 2001Date of Patent: June 3, 2003Assignee: Vertex Pharmaceuticals IncorporatedInventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
-
Patent number: 6552036Abstract: This invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as &dgr;-opioid or &mgr;-opioid receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.Type: GrantFiled: February 22, 2001Date of Patent: April 22, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Robert E. Boyd, John R. Carson, Steven J. Coats, Lou Anne Neilson, Philip M Pitis, Wu-Nan Wu
-
Patent number: 6444663Abstract: This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.Type: GrantFiled: December 5, 2000Date of Patent: September 3, 2002Assignee: Idun Pharmaceuticals, Inc.Inventors: Donald S. Karanewsky, Steven D. Linton
-
Patent number: 6407083Abstract: Compounds represented by the following formula I: in which: R1 to R5 can have various meanings of which alkyl, substituted or non-substituted aryl, and m is equal to 0 or 1, X is selected from (CR6R7)n in which n=0 or 1, and CO are disclosed. These compounds are useful as anti-tumor drugs, especially with pro-oxidizing activity.Type: GrantFiled: August 28, 2000Date of Patent: June 18, 2002Assignee: Oxis International, Inc.Inventors: Jinzhu Xu, Georges Appere, Jean Chaudiere, Jean-Claude Yadan
-
Patent number: 6353018Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: October 19, 1999Date of Patent: March 5, 2002Assignees: Novo Nordisk A/S, Dr. Reddy's Research FoundationInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6258804Abstract: Described are compound of the formula (I) defined herein which are useful, for example, in the treatment of diabetes. Also described is a method for preparing the compounds.Type: GrantFiled: July 14, 2000Date of Patent: July 10, 2001Assignee: Merck Patent GmbHInventors: Daniel Ruggiero, Nicolas Wiernsperger, Gérard Patereau, Gérard Moinet
-
Patent number: 6218549Abstract: The subject invention provides a bicyclic aminoimidazole compound, a hydroxyalkyl aminoimidazole compound, a bicyclic pyrrole compound, a hymenin compound, an aldehyde aminoimidazole compound, a ketal aminoimidazole compound, a tricyclic compound, and a tetrahydropurine compound. The subject invention also provides for processes for preparing the compounds.Type: GrantFiled: November 16, 1999Date of Patent: April 17, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: David A. Horne, Kenichi Yakushijin
-
Patent number: 5965728Abstract: A process for the preparation of a salt of clavulanic acid, wherein clavulanic acid in solution in a wholly or partly water-imiscible organic solvent is contacted in a region of high turbulence and/or shear stress, with a salt precursor compound to form a solution of the salt of clavulanic acid in an aqueous phase, then the organic solvent and aqueous phases are physically separated during a separation step, followed by a further processing step in which the said salt of clavulanic acid is isolated from solution as a solid.Type: GrantFiled: August 21, 1996Date of Patent: October 12, 1999Assignee: SmithKline Beecham PLCInventors: Michael Alan Cook, Geoffrey Clive Webb
-
Patent number: 5932724Abstract: The present invention provides an efficient process for the recovery of caprolactam from polycaprolactam-containing waste material. The present process for depolymerizing multi-component waste material comprising polycaprolactam and non-polycaprolactam components to form caprolactam comprises the step of: in the absence of added catalyst, contacting the multi-component waste material with superheated steam at a temperature of about 250.degree. C. to about 400.degree. C. and at a pressure within the range of about 1 atm to about 100 atm and substantially less than the saturated vapor pressure of water at the temperature wherein a caprolactam-containing vapor stream is formed. The formed caprolactam may then be used in the production of engineered resins and fibers.Type: GrantFiled: April 16, 1997Date of Patent: August 3, 1999Assignees: AlliedSignal Inc., DSM N.V.Inventors: Stylianos Sifniades, Alan Bart Levy, Jan Agnes Jozef Hendrix